Table 1.
Patient demographics: age, overall survival, progression-free survival, sex, radiation dose for dynamic contrast enhanced CT, pathology, clinical stage, immunotherapy agent used and line of treatment
| Characteristics | Description | Total (N = 33) |
|---|---|---|
| Age | Years of age | 69.9 (CI95% 67.2 to 72.6) |
| OS | Months | 21.7 (Min: 1 to Max: 42) |
| PFS | Months | 6.1 (Min: 1 to Max: 42) |
| Sex | Male | 15 |
| Female | 18 | |
| Radiation dose | DLP | 970.6 (CI95% 913.8 to 1027.4) |
| Primary tumor pathology | Adenocarcinom | 25 |
| Squamous Cell Carcinoma | 6 | |
| Unclassified NSCLC | 2 | |
| Clinical stage | IIIB | 1 |
| IIIC | 1 | |
| IVA | 18 | |
| IVB | 8 | |
| Recidivation | 5 | |
| Immunotherapy agent | Pembrolizumab | 31 |
| Nivolumab | 1 | |
| Atezolizumab | 1 | |
| Line of treatment | First | 25 |
| Second | 5 | |
| Third | 3 |
DLP Dose Length Product, NSCLC Non-Small Cell Lung Cancer